- |||||||||| risperidone / Generic mfg., fluoxetine / Generic mfg.
Journal: Co-existence of Capgras syndrome and OCD in children: Case studies. (Pubmed Central) - Jun 24, 2025
Our treatment approach combines antipsychotic medication, selective serotonin reuptake inhibitors (SSRIs), and gradual exposure therapy accompanied by parent training, has yielded favorable outcomes in managing the patients' psychiatric symptoms.Discussion and ConclusionWe provide insights into CS with comorbid OCD in children and discuss the behavioral treatment approach employed in our cases. We also discuss similar cases of CS comorbid with OCD from the English literature.
- |||||||||| lamotrigine liquid oral suspension / OWP Pharma
Journal: Clinical signatures of SYNGAP1-related disorders through data integration. (Pubmed Central) - Jun 24, 2025
We also discuss similar cases of CS comorbid with OCD from the English literature. We delineated the seizure, developmental, and behavioral trajectories in SYNGAP1-related disorders, to improve diagnosis, prognosis, and clinical care, and facilitating clinical trial readiness.
- |||||||||| Ztalmy (ganaxolone oral) / Marinus, Xcopri (cenobamate) / SK Bio, Fintepla (low-dose fenfluramine) / UCB
Journal: Antiseizure Medications: Advancements, Challenges, and Prospects in Drug Development. (Pubmed Central) - Jun 24, 2025
The review also discusses the development of new potential ASMs, including modifying existing ASMs to improve efficacy and tolerability. Furthermore, we expound on the modulation of ?- aminobutyric acid type A receptor (GABAAR) as a strategy for the treatment of epilepsy and the identification of a GABAAR agonist, isoguvacine, as a potential ASM.
- |||||||||| ecopipam (PSYRX 101) / Paragon Biosci
Journal: D1 dopamine receptor antagonists as a new therapeutic strategy to treat autistic-like behaviours in lysosomal storage disorders. (Pubmed Central) - Jun 24, 2025
In contrast, ecopipam, a D1 antagonist already used in the clinic for other neuropsychiatric disorders, rescues ALBs, cognition, D1 hyperactivity, and does not worsen neurodegenerative signs. These results align with recent evidence highlighting the clinical relevance of D1 antagonists for neuropsychiatric disorders and pave the way for their use in managing psychotic symptoms in neurodegenerative disorders such as dementia with Lewy bodies.
- |||||||||| haloperidol / Generic mfg., amphetamine / Generic mfg.
Journal: Acid sphingomyelinase activity suggests a new antipsychotic pharmaco-treatment strategy for schizophrenia. (Pubmed Central) - Jun 24, 2025
Short-term haloperidol (HAL) treatment reversed behavioral symptoms and the ASM activity...HAL and KARI201 antipsychotic effects were associated with targeting expression of other schizophrenia associated genes like Col6a3, Slc22a8, and Bmal1, or Nr2f6a, respectively, but none affecting expression of sphingolipid regulating genes. Our data provide new insight into a potentially pathogenic mechanism of schizophrenia and suggest a new pharmaco-treatment strategy with reduced side effects.
- |||||||||| imipramine / Generic mfg., desipramine / Generic mfg., amitriptyline / Generic mfg.
Journal: Tricyclic antidepressants dose-dependently modulate the biphasic activity of the TRPC5 channel through opioid receptors. (Pubmed Central) - Jun 24, 2025
The biphasic modulation of TRPC5 by TCAs may contribute to a wide spectrum of cardiovascular and neurological manifestations, depending on the dosage and clinical application. Overall, these findings enhance the pharmacological understanding of the molecular mechanisms underlying the actions of TCAs and emphasize the need for more targeted therapeutic approaches.
- |||||||||| imipramine / Generic mfg., escitalopram / Generic mfg.
Preclinical, Journal: Asiatic acid potentiates the activity of common antidepressant drugs in mice. (Pubmed Central) - Jun 24, 2025
Our findings give a new light on the potential use of asiatic acid in the management of depression. The terpenoid has antidepressant properties, potentially making it a valuable addition/adjunct to conventional treatment.
- |||||||||| Journal: The Role of Toxins and Fillers in Optimizing Perioral Rejuvenation. (Pubmed Central) - Jun 24, 2025
Changes in the perioral region are significant contributors to the visible signs of aging.Ideal candidates for perioral rejuvenation with toxin and filler are individuals experiencing age-related rhytids or volume loss who are interested in minimally invasive, nonsurgical interventions.Neurotoxins like Botox, Xeomin, Dysport, Jeuveau, and Daxxify are used to relax muscles that contribute to rhytids...Dermal fillers such as hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid restore volume in areas like the nasolabial folds, lips, marionette lines, chin, prejowl sulcus, and perioral rhytids.Neurotoxins and dermal fillers offer effective, minimally invasive solutions for perioral rejuvenation. With an understanding of underlying anatomy, proper patient selection, and precise injection techniques, facial plastic surgeons can achieve natural, youthful results with minimal downtime.
- |||||||||| Journal: Cefotaxime-associated encephalopathy in peritoneal dialysis patients: A case report. (Pubmed Central) - Jun 24, 2025
This highlights the necessity of vigilance in monitoring drug-related complications for timely detection of encephalopathic symptoms and development of individualized treatment strategies. We acknowledge that cefotaxime may increase the risk of CAE in patients on peritoneal dialysis, necessitating heightened awareness among physicians.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Retrospective data, Journal: Long-Term Symptomatic and Functional Remission with Paliperidone Palmitate 6-Monthly Treatment in Schizophrenia: A 3-Year Post-Hoc Analysis. (Pubmed Central) - Jun 24, 2025
P3
In addition, >56% of patients who transitioned from PP3M to PP6M or continued PP6M treatment had sustained combined (symptomatic and functional) remission at the OLE endpoint. These findings support the long-term efficacy of PP3M and PP6M, highlighting the potential benefits of transitioning to longer acting antipsychotic formulations in achieving and sustaining both symptomatic stability and functional improvement in adults with schizophrenia.
- |||||||||| Review, Journal: Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies. (Pubmed Central) - Jun 24, 2025
To date, five different risperidone LAI formulations have been marketed - including a second biweekly microsphere injection (LY03004), a newer monthly intramuscular formulation using in situ microparticles (ISM) technology that does not require an oral risperidone run-in, and two subcutaneous formulations (RBP-7000 and TV-46000)...To facilitate this, healthcare providers should develop a comprehensive understanding of these formulations to select the most suitable option. While risperidone ISM, RBP-7000, and TV-46000 may enhance treatment feasibility and adherence, further research is needed to build an evidence base comparable to that available for BW-RLAI, particularly in the treatment of BD.
- |||||||||| trazodone ER / Generic mfg.
Journal: Trazodone in psychogeriatric care (Pubmed Central) - Jun 24, 2025
It was demonstrated that regular trazodone use is associated with delayed cognitive decline in humans with a diagnosis of Alzheimer's dementia. However, it is currently unclear if trazodone features significant neuroprotective effects in humans.
- |||||||||| roluperidone (MIN-101) / Mitsubishi Tanabe, Minerva Neurosciences
Journal, Monotherapy: Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia. (Pubmed Central) - Jun 24, 2025
The patients who were symptomatic stable for 3 or 6 months before antipsychotic drug withdrawal, showed a very low prevalence of psychotic symptoms worsening over 6 or 9 months trials duration. Focus: Treatment of primary negative symptoms in a subgroup of patients suffering from schizophrenia.
- |||||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Review, Journal: Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine. (Pubmed Central) - Jun 24, 2025
Taken overall, the findings from several head-to-head studies indicated a functional advantage of vortioxetine compared with other classes of antidepressants and demonstrated the effectiveness of vortioxetine as first-line treatment while also confirming its effectiveness in improving functional outcomes when given later in the treatment journey. In summary, vortioxetine is an effective treatment option for improving functional outcomes in people living with MDD.
- |||||||||| Journal: Neurostimulant Use for Rehabilitation and Recovery After Stroke: A Narrative Literature Review. (Pubmed Central) - Jun 24, 2025
In conclusion, there are promising results of positive effects of neurostimulants with few side effects, though studies are limited by heterogeneous designs and small sample sizes. Neurostimulant efficacy must be assessed in conjunction with specific rehabilitation modalities as part of larger, well-designed studies to best understand their effects on impairment.
- |||||||||| Trintellix (vortioxetine) / Lundbeck, Takeda
Trial completion: Postoperative Pain Management Following Laparoscopic Cholecystectomy (clinicaltrials.gov) - Jun 23, 2025
P3, N=86, Completed,
Even in the context of the French free-of-charge healthcare system, major spatial inequities exist in access to these medications for youths, partly underlaid by social disparities and medical demography. Recruiting --> Completed
- |||||||||| lithium carbonate ER / Generic mfg., quetiapine / Generic mfg.
Journal: Mood stabilizers: Insights from users' perceptions. (Pubmed Central) - Jun 23, 2025
The findings of this study underscore the significant role that emotional and psychological side effects play in treatment dissatisfaction during MSA use. Both research and clinical decisions should consider the subjective experiences of patients undergoing MSA treatment.
- |||||||||| Vyleesi (bremelanotide) / Palatin Technologies, Addyi (flibanserin) / Sprout Pharma
Retrospective data, Journal: Title: Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-analysis of Treatment Options. (Pubmed Central) - Jun 22, 2025
This broader perspective offers a starting point for clinicians, including gynecologists, who frequently serve as the first point of care for female sexual dysfunction. Conclusions regarding most other treatments could not be drawn due to limited numbers of studies of FSD excluding pain, heterogeneous terminology for DAO disorders, and varying outcome measures across studies.
- |||||||||| escitalopram / Generic mfg.
Journal: Norepinephrine system dysconnectivity in major depressive disorder: the effect of short term SSRI treatment. (Pubmed Central) - Jun 22, 2025
As expected, no significant changes of the LCNE connectivity occurred with 8-weeks of escitalopram treatment. We provide robust evidence for a striking sensory-multimodal imbalance in LCNE system connectivity across three independent samples, with a potential link to NE transporter chemoarchitecture, that is not alleviated by a serotonin selective antidepressant agent.
- |||||||||| Antibiotic Resistome Shaped by Complex Pollutant Interactions: Microplastics, Heavy Metals, and PPCPs in Wastewater Treatment Plants (Exhibit Hall) - Jun 22, 2025 - Abstract #ASMMicrobe2025ASM_Microbe_2700;
Heavy metals (e.g., Mn, Fe, Co, As) and PPCPs (e.g., amitriptyline, acetaminophen, gemfibrozil) showed significant positive correlations with total ARG abundance in the effluent (p < 0.05), highlighting their role in ARG dissemination. These findings underscore the need for enhanced wastewater treatment to mitigate ARG spread and address the combined effects of emerging contaminants.
- |||||||||| chlorpromazine / Generic mfg.
Investigating Chlorpromazine's Role in Attenuating Quorum Sensing and Biofilm in Gram-Negative Bacteria (Exhibit Hall) - Jun 22, 2025 - Abstract #ASMMicrobe2025ASM_Microbe_2021;
The study shows the potential of chlorpromazine as a quorum sensing inhibitor, offering a promising strategy for managing bacterial infections by targeting virulence factors rather than relying solely on traditional antibiotics. Further research is warranted to explore the underlying mechanisms of chlorpromazine's action and its applicability in clinical settings.
- |||||||||| fluoxetine / Generic mfg.
Serotonin and Indole Sensing in Virulence Regulation of Enteric Pathogens (Exhibit Hall) - Jun 22, 2025 - Abstract #ASMMicrobe2025ASM_Microbe_1864;
The findings of our study establish evidence for the presence of an important resistance mechanism by microbiota against enteric pathogens. Since many GI pathogens encode CpxA, it is possible to enhance the resistance against not only EHEC but against various infections through manipulating indole and serotonin levels by already established drugs (e.g., Prozac) and by manipulation of microbiota.
- |||||||||| Atzumi (dihydroergotamine) / Shin Nippon Biomedical Labs
Journal: The Ongoing Expansion of the Medically Important Scorpions in Southern South America. (Pubmed Central) - Jun 20, 2025
We present their current suitable areas and the potential future distribution up to 2070...We conclude that, besides synanthropic capabilities, parthenogenesis is the main factor favoring the expansion of some of these species. We also conclude that interactions between invasive Tityus species may hinder their expansion process due to potential competition or exclusion mechanisms.
- |||||||||| frovatriptan / Generic mfg.
Journal: Allegro-FM: Toward an Equivariant Foundation Model for Exascale Molecular Dynamics Simulations. (Pubmed Central) - Jun 20, 2025
With its computationally efficient, strictly local network architecture, Allegro-FM scales up to multibillion-atom systems with a parallel efficiency of 0.975 on the exaflop/s Aurora supercomputer at Argonne Leadership Computing Facility. The approach presented in this work demonstrates the potential of the foundation model for novel materials design and discovery based on large-scale atomistic simulations.
|
